高级检索
当前位置: 首页 > 详情页

Baicalin attenuates LPS-induced alveolar type II epithelial cell A549 injury by attenuation of the FSTL1 signaling pathway via increasing miR-200b-3p expression.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Tuberculosis Diseases, Third People's Hospital of Kunming City, China. [2]Department of Nephrology, The Sixth Affiliated Hospital of Kunming Medical University, China. [3]Department of Emergency Medicine, First Affiliated Hospital of Kunming Medical University, China.
出处:
ISSN:

关键词: Baicalin alveolar type II epithelial cells inflammatory response miR-200b-3p FSTL1

摘要:
In China, baicalin is the main active component of Scutellaria baicalensis, which has been used in the treatment of inflammation-related diseases, such as inflammation-induced acute lung injury. However, its specific mechanism remains unclear. This study examined the protective effect of baicalin on LPS-induced inflammation injury of alveolar epithelial cell line A549 and explored its protective mechanism. Compared with the LPS-induced group, the proliferation inhibition rates of alveolar type II epithelial cell line A549 intervened by different concentrations of baicalin decreased significantly, as did the levels of inflammatory factors IL-6, IL-1β, prostaglandin 2 and TNF-α in the supernatant. The expression levels of inflammatory proteins inducible NO synthase (iNOS), NF-κB65, phosphorylated ERK (p-ERK1/2), and phosphorylated c-Jun N-terminal kinase (p-JNK1) significantly decreased, as did the protein expression of follistatin-like protein 1 (FSTL1). In contrast, expression of miR-200b-3p significantly increased in a dose-dependent manner. These results suggested that baicalin could significantly inhibit the expression of inflammation-related proteins and improve LPS-induced inflammatory injury in alveolar type II epithelial cells. The mechanism may be related to the inhibition of ERK/JNK inflammatory pathway activation by increasing the expression of miR-200b-3p. Thus, FSTL1 is the regulatory target of miR-200b-3p.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 4 区 生物学
小类 | 4 区 微生物学 4 区 医学:研究与实验 4 区 生化与分子生物学 4 区 免疫学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 生化与分子生物学 4 区 免疫学 4 区 医学:研究与实验 4 区 微生物学
JCR分区:
出版当年[2021]版:
Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q3 MICROBIOLOGY Q4 IMMUNOLOGY
最新[2023]版:
Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Q3 IMMUNOLOGY Q3 MICROBIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Department of Tuberculosis Diseases, Third People's Hospital of Kunming City, China.
共同第一作者:
通讯作者:
通讯机构: [3]Department of Emergency Medicine, First Affiliated Hospital of Kunming Medical University, China. [*1]Department of Emergency Medicine, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Wuhua District, Kunming, Yunnan Province, 650032, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:53625 今日访问量:0 总访问量:1665 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)